Getting an early heads-up is only half the job.
The other half is knowing what to do with it. A likely guideline update might give your team time to prepare. A possible coverage change could affect when you invest, launch, or revisit a strategy. The window is the deadline less the evidence cutoff: a record fact, not a performance measure.
· Phase 0 · registry-derived · not a performance measure
Records 68
Median window 73d
Middle half 53–114d
Range 30–365d
The distribution
30 days or less 1
31–90 days 39
91–180 days 24
181–365 days 4
More than a year 0
Each bar is the number of records whose window falls in that band. The counts sum to 68.
Every record, sorted
The shortest windows
- FF-007 · Bepirovirsen · hepatitis B approval 30d · by Oct 26, 2026
- FF-016 · Epcoritamab combination · guidance publication 32d · by Oct 28, 2026
- FF-010 · INO-3107 · papillomatosis approval 34d · by Oct 30, 2026
- FF-012 · Mitapivat · sickle cell supplement approval 36d · by Nov 1, 2026
- FF-017 · Inavolisib combination · guidance publication 38d · by Nov 3, 2026
The longest windows
- FF-001 · Sunvozertinib · first-line guideline listing 365d · by Jul 31, 2027
- FF-004 · Sunvozertinib · FDA approval before NCCN listing 312d · by Jul 31, 2027
- FF-002 · Sunvozertinib · first-line approval 312d · by Jul 31, 2027
- FF-003 · Sunvozertinib · first-line approval by March 190d · by Mar 31, 2027
- FF-063 · Zanzalintinib · metastatic colorectal cancer approval 133d · by Mar 3, 2027